胡萝卜毒素 | 14445-65-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 胡萝卜毒素
• 英文名称: heptadeca-1,10t-diene-5,7-diyn-3-ol
• 英文别名: 1,10-Heptadecadiene-5,7-diyn-3-OL, (E)-；(10E)-heptadeca-1,10-dien-5,7-diyn-3-ol
• CAS: 14445-65-9
• 化学式: C₁₇H₂₄O
• 分子量: 244.377
• InChiKey: FXXPOEXJAUWMMJ-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  胡萝卜毒素 在 platinum on activated charcoal 氢气 作用下， 以 乙醇 、 苯 为溶剂， 生成 3-heptadecanol
  参考文献：
  名称：

  胡萝卜素的天然毒素-胡萝卜素的结构

  摘要：

  的物质已经从公共胡萝卜，的提取物中分离胡萝卜，这是有毒的生物测定生物体水蚤和小鼠。物理和化学证据表明，这种化合物称为胡萝卜素，是反式-1,10-十七碳二烯-5,7-二炔-3-醇（III）。

  DOI：

  10.1016/s0040-4020(01)83330-5

文献信息

• LOW CALORIE, NON-GRAIN, VEGAN TREATS FOR COMPANION ANIMALS
  申请人：AKAMATSU John William

  公开号：US20120309855A1

  公开（公告）日：2012-12-06

  The invention provides methods of using hay, vegetable and/or fruit pulp, and a hydrocolloid for making animal food; and the food products produced using such methods; and the products then being dried through low-temperature dehydration. The animal food products are free of gluten, grains, legumes, nuts, animal-products, sweeteners, and fats.
• US9023409B2
  申请人：——

  公开号：US9023409B2

  公开（公告）日：2015-05-05
• [EN] COMBINING SERMS, SARMS, AND CANNABINOIDS FOR IMPROVING SAFETY AND EFFICACY OF ENDOCRINE THERAPIES<br/>[FR] COMBINAISON DE SERM, DE SARM ET DE CANNABINOÏDES DESTINÉE À AMÉLIORER LA SÉCURITÉ ET L'EFFICACITÉ D'ENDOCRINOTHÉRAPIES
  申请人：TESS VENTURES INC

  公开号：WO2020160452A1

  公开（公告）日：2020-08-06

  The present invention provides methods for the alleviation of symptoms of diseases or medical conditions impacted by dysfunction of the endocannabinoid system in a subject, the methods comprising administering an effective amount of a SERM, SARM, or other endocrine agent in combination with an effective amount of a cannabinoid or cannabimimetic agent or combination of such agents tailored to a subject's specific symptoms. In particular embodiments, the cannabinoid or cannabimimetic agent or combination of such agents alleviate chemotherapy-induced nausea and vomiting in a subject, while a prescription SERM treats the immuno-suppression associated with cannabinoid-based therapy. In some embodiments, the side effects associated with endocrine therapies in a subject are prevented or limited by administering cannabinoid or cannabimimetic agents or combinations of such agents to the subject. In other embodiments, the side effects associated with cannabinoid or cannabimimetic-based therapies in a subject are prevented or limited by administering a prescription endocrine therapy to the subject.